Merete Krogh

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

Per Pfeiffer, Mette Yilmaz, Sören Möller et al. · The Lancet Oncology · 2020 · 224 citations

Gastrointestinal Oncology, Medicine, Pathology +5

LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

Ramón Salazar, S. Tafuto, Merete Krogh et al. · Annals of Oncology · 2022 · 30 citations · Full text

Advanced Progressive Pannets, Seqtor Study, Reverse Sequence +11

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma

Merete Krogh, Ib Jarle Christensen, Marna G. Bouwhuis et al. · Melanoma Research · 2016 · 26 citations

Nordic Ifn Trial, Immunology, Pathology +18

S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma

Stine Brændegaard Winther, Jon Kroll Bjerregaard, Katrine R. Schønnemann et al. · Cancer Chemotherapy and Pharmacology · 2018 · 10 citations